<DOC>
	<DOCNO>NCT00291135</DOCNO>
	<brief_summary>A pilot study assess effect six month letrozole breast tissue risk marker postmenopausal woman hormone replacement therapy high risk develop breast cancer .</brief_summary>
	<brief_title>Protocol Women Increased Risk Developing Breast Cancer</brief_title>
	<detailed_description>A pilot study letrozole postmenopausal woman hormone replacement therapy high risk develop breast cancer . Subjects hyperplasia atypia ( borderline Epithelial Hyperplasia/Atypical Hyperplasia ) evidence Estrogen Receptor expression random periareolar fine needle aspiration baseline serum estradiol level less equal 150 pg/ml . The feasibility perform RT-qPCR breast specimen aromatase expression also do baseline .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>evidence hyperplasia with/without atypia upon random periareolar fine needle aspiration breast hormone replacement therapy postmenopausal increase risk develop breast cancer base personal family history never take aromatase inhibitor selective estrogen receptor modulators last six month woman high risk breast cancer old 18 year anticoagulant mark breast tenderness pregnant within twelve month breast feeding/childbirth</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>breast atypia</keyword>
	<keyword>open label pilot study</keyword>
	<keyword>letrozole</keyword>
	<keyword>fine needle aspiration</keyword>
	<keyword>high risk breast cancer</keyword>
	<keyword>breast epithelial hyperplasia</keyword>
	<keyword>Ki-67</keyword>
	<keyword>hormone plus chemoprevention</keyword>
	<keyword>chemoprevention</keyword>
</DOC>